Floatz logo

Tezemlimogene Daxadenorepvec

Liver Metastasis Colon Cancer

DNAtrix, Inc.gene_therapyPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Liver Metastasis Colon Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Fudan University
Phase 4BBB
Fruquintinib
Peking University
Phase 3BBB
DEXAMETHASONE
Fudan University
Phase 3BB
Capecitabine
Jun Huang
Phase 3BB
Irinotecan
Jun Huang
Phase 3BB

View all 50 →

Same molecule, other indications

Tezemlimogene Daxadenorepvec is also rated in:

renal cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
periampullary adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
gastrointestinal stromal tumorDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →